Table 1.
Year | Active compound | Trade name | Disease treated |
---|---|---|---|
2015 |
Insulin degludec Chain A (GIVEQCCTSICSLYQLENYCN) Chain B (FVNQLCGSHLVEALYLVCGERGFFYTP) |
Tresiba® | Diabetes |
2016 |
Adlyxin (HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKK) |
Lixisenatide® | Diabetes |
2017 |
Abaloparatide (AVSEHQLLHDKGKSIQDLRRRELLEKLLXKLHTA) |
Tymlos® | Osteoporosis |
2017 |
Angiotensin II (DRVYIHPF) |
Giapreza® | Hypotension |
2017 |
Etelcalcetide [Ac-(CARRRAR)D-NH2] |
Parsabiv® | Hyperparathyroidism |
2017 |
Plecanatide (NDECELCVNVACTGCL) |
Trulance® | Chronic idiopathic constipation |
2017 |
Semaglutide (HXEGTFTSDVSSYLEGQAAKEFIAWLVRGRG) |
Ozempic® | Diabetes |
2018 |
177Lu DOTATATE (FDCYWDKTCT) |
Lutathera® | Neuroendocrine tumors, theranostic |
2019 |
68 Ga DOTATOC (FDCYDWKTCT) |
Edotreotide Gallium GA-68® | Neuroendocrine tumors, diagnostic |
2019 |
Afamelanotide (Ac-SYSXEHFDRWGKPV-NH2) |
Scenesse® | Skin damage and pain |
2019 |
Bremelanotide (DHFDRWK) |
Vyleesi® | Women hypoactive sexual desire |
2020 |
Bulevirtide acetate (GTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPNKDHWPEANKVG) |
Hepcludex® | Antiviral Hepatitis delta virus infection |
2020 |
Somapacitan (FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSCVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF) |
Sogroya® | Growth hormone deficiency |
2020 |
Teriparatide acetate (SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF) |
Forteo/Forsteo® | Osteoporosis |
2021 |
Dasiglucagon (HSQGTFTSDYSKYLDXARAEEFVKWLEST) |
Zegalogue® | Hypoglycemia |
2021 |
Pegcetacoplan (ICVWQDWGAHRCTXK) |
Empaveli® | Nocturnal hemoglobinuria |
2021 |
Difelikefalin (FFLK)D-[ω(4-aminopiperidine-4-carboxylic acid)]-OH |
Korsuva® | Chronic kidney diseases |
2021 |
Vosoritide (PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC) |
Voxzogo® | Achondroplasia and open epiphyses |